Core Insights - The China-ASEAN Regional Pharmaceutical Trading (Procurement) Platform has successfully surpassed a transaction amount of 10 million yuan, facilitating cross-border cooperation in the pharmaceutical sector between China and ASEAN countries [1] - The platform, launched on January 9, 2025, has significantly streamlined the procurement process for Chinese pharmaceuticals, enabling faster and more efficient transactions [1] Group 1: Platform Achievements - The platform has attracted 224 domestic pharmaceutical companies, showcasing 1,020 types of drugs and 2,418 categories of medical consumables [1] - It has also welcomed 19 foreign buyers, indicating a growing international interest in the platform [1] - The platform has received over 170 procurement requests for pharmaceutical products from countries like Vietnam and Thailand, contributing to a diverse trading landscape [1] Group 2: Impact on Trade - The procurement process has been simplified, allowing companies to complete tasks that previously took months in just weeks or even days, enhancing responsiveness to market demands [1] - Thai company Pinyo Pharmacy Ltd successfully procured piperacillin sodium and tazobactam injection from Qilu Pharmaceutical Group, highlighting the platform's role in providing high-quality and affordable medication to Thai citizens [1] - The platform's data analysis capabilities facilitate precise matching between supply and demand, further optimizing the trading process [1] Group 3: Future Developments - The Guangxi Medical Security Bureau plans to continue developing the platform and explore new models for regional healthcare, insurance, and pharmaceutical cooperation [2] - There is an emphasis on deepening exchanges and practical cooperation in medical insurance policies and medical technologies between China and ASEAN countries [2] - The initiative aims to enhance mutual understanding and promote the pharmaceutical industry through "small but beautiful" projects [2]